Skip to content

GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles

Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Long Gonadotropin Releasing Hormone Agonist Protocol Cycles

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02312076
Enrollment
200
Registered
2014-12-09
Start date
2016-09-09
Completion date
2024-12-31
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Luteal phase support, ICSI, GnRHa

Brief summary

Evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist (GnRHa) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (ICSI) following long GnRHa protocol

Detailed description

Endometrial preparation for embryo transfer (ET) will be started after oocyte retrieval by giving 800 mg/day natural progesterone vaginal supplement + 4 mg/day estradiol oral supplement. The patients will be randomly divided into 2 groups for luteal phase support: (i) Group A (GnRHa group) in which the luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval, and (ii) Group B (control group) in which the luteal phase support will be continued only by the same regimen started on the day of oocytes retrieval until 2 weeks after ET

Interventions

DRUGTriptorelin

Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

* Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRHa.

Exclusion criteria

* Moderate or severe endometriosis. * Hydrosalpinx. * Uterine abnormalities. * Myoma. * Previous uterine surgery.

Design outcomes

Primary

MeasureTime frameDescription
Clinical pregnancy rate6 weeks after embryo transferNumber of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 4-6 weeks after the ET) divided by the number of ET procedures

Secondary

MeasureTime frameDescription
Implantation rate6 weeks after embryo transferNumber of gestational sacs on TVS scan at 4-6 weeks after ET divided by the number of transferred embryos
Miscarriage rate12 weeks gestational ageNumber of first trimester miscarriages (before 12 weeks gestational age) divided by the number of clinical pregnancies

Countries

Egypt

Contacts

Primary ContactMohamed S Abdelhafez, Dr
msabdelhafez@gmail.com+201144523366

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026